Brief: Lexicon Pharmaceuticals Resubmits Marketing Application For Diabetes Drug
21/06/2024 13:40
June 21 (Reuters) - Lexicon Pharmaceuticals Inc
LXRX.O :
* LEXICON PHARMACEUTICALS RESUBMITS SOTAGLIFLOZIN NDA FOR
TYPE 1
DIABETES
* LEXICON PHARMACEUTICALS INC - CO ANTICIPATES SIX MONTH
REVIEW
AND POTENTIAL LAUNCH IN EARLY 2025
Source text for Eikon: ID:nGNX1GWKB8
Further company coverage: LXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview